Is Nidan Laborator. overvalued or undervalued?

As of 23 September 2025, the valuation grade for Nidan Laborator. has moved from very attractive to attractive. The company appears to be undervalued, given its current PE ratio of 13.55, an EV to EBITDA ratio of 7.11, and a Price to Book Value of 0.39. These ratios suggest that the company is trading at a significant discount compared to its peers, particularly when compared to Max Healthcare, which has a PE ratio of 93.36, and Apollo Hospitals, with a PE ratio of 70.26.
In the context of peer comparison, Nidan Laborator.'s PEG ratio stands at 0.00, indicating that it may be undervalued relative to its growth prospects. The company's return on capital employed (ROCE) is 3.44%, and return on equity (ROE) is 2.90%, which, while modest, may improve if the company capitalizes on its attractive valuation. Notably, Nidan Laborator. has underperformed the Sensex over the past year, with a stock return of -43.05% compared to the Sensex's -2.97%, reinforcing the notion that the stock may be undervalued in the current market environment.